Clinical Trial

Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

Study acronym: MINIMA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To determine if it is feasible to use neoadjuvant immunotherapy (or immunotherapy plus chemotherapy) to reduce treatment intensity and improve long-term quality of life while maintaining very high cure rates.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-07-23; most recent amendment 2026-02-27.
Status change: Not Yet Recruiting → Recruiting 2022-01-10
Trial Details
NCT Number NCT04988074
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Regeneron Pharmaceuticals
Conditions HPV-Related Squamous Cell Carcinoma
Enrollment 32 participants
Start Date 2021-12-13
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-03